<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01745965</url>
  </required_header>
  <id_info>
    <org_study_id>WSG-AM06/ADAPT HER2+/HR+</org_study_id>
    <nct_id>NCT01745965</nct_id>
  </id_info>
  <brief_title>A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.</brief_title>
  <acronym>ADAPT; T-DM1</acronym>
  <official_title>A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West German Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>West German Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial to optimize neoadjuvant therapy for HER overexpression and co-expressing of hormone&#xD;
      receptors(ER and/or PR) breast cancer (HEr2+/HR+).&#xD;
&#xD;
      A new high potential trastuzumab conjugate T-DM1(trastuzumab was linked with the cytotoxic&#xD;
      agent mertansine DM1)was tested with endocrine therapy and without against a standard arm&#xD;
      with trastuzumab and endocrine therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the neoadjuvant therapy Patients with HER2+/HR+ (HER2+ and ER+ and/or PR+) tumor will receive&#xD;
      single agent T-DM1 for 12 weeks (3,6 mg/kg q3w) with or without standard endocrine therapy&#xD;
      (tamoxifen in premenopausal women and an aromatase inhibitor in postmenopausal women, if not&#xD;
      contraindications are present, in a standard daily dosage). The control group will receive&#xD;
      trastuzumab in 3-weekly schedule (8 mg/kg as loading dose and then 6 mg/kg q3w) in&#xD;
      combination with the same standard endocrine therapy, if no contraindications are existent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">November 2012</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the pCR rates in patients with HER2+/HR+ breast cancer treated by preoperative T-DM1 with or without standard endocrine therapy or trastuzumab with endocrine therapy.</measure>
    <time_frame>After 12 weeks</time_frame>
    <description>pCR will be measured after 12 weeks of randomized treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of dynamic testing (based on proliferation/apoptosis changes in serial biopsy and imaging by MRI) after three weeks of treatment as a surrogate parameter for response.</measure>
    <time_frame>after 3 weeks of treamtment</time_frame>
    <description>Response: pCR (residual cancer burden (RCB) 0-1) or resistance/low response (RCB II-III or progressive disease)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of dynamic test regarding prediction of 5-year event-free survival (EFS)</measure>
    <time_frame>5 year after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 year after treamtment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity/cardiac safety</measure>
    <time_frame>5 years after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall safety in the three treatment arms</measure>
    <time_frame>5 years after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (HRQL)</measure>
    <time_frame>After 5 year after treatment of last patient</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>T-DM1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single agent T-DM1 for 12 weeks (3,6 mg/kg q3w)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T-DM1 + endocrine therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single agent T-DM1 for 12 weeks (3,6 mg/kg q3w) with standard endocrine therapy (tamoxifen in premenopausal women and an aromatase inhibitor in postmenopausal women, if no contraindications are present, in a standard daily dosage).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trastuzumab + endocrine therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group will receive trastuzumab in 3-weekly schedule (8 mg/kg as loading dose and then 6 mg/kg q3w)with endocrine therapy tamoxifen in premenopausal women and an aromatase inhibitor in postmenopausal women, if not contraindications are present, in a standard daily dosage).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T-DM1</intervention_name>
    <arm_group_label>T-DM1</arm_group_label>
    <arm_group_label>T-DM1 + endocrine therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <arm_group_label>Trastuzumab + endocrine therapy</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients, age at diagnosis 18 years and above (consider patients at 70 years&#xD;
             and above for ADAPT Elderly)&#xD;
&#xD;
          -  Histologically confirmed unilateral primary invasive carcinoma of the breast&#xD;
&#xD;
          -  Clinical T1 - T4 (except inflammatory breast cancer)&#xD;
&#xD;
          -  All clinical N (cN)&#xD;
&#xD;
          -  No clinical evidence for distant metastasis (M0)&#xD;
&#xD;
          -  Known HR status and HER2 status (local pathology) Tumor block available for central&#xD;
             pathology review&#xD;
&#xD;
          -  Performance Status ECOG ≤ 1 or KI ≥ 80%&#xD;
&#xD;
          -  Negative pregnancy test (urine or serum) within 7 days prior to start of induction&#xD;
             treatment in premenopausal patients&#xD;
&#xD;
          -  Written informed consent prior to beginning specific protocol procedures, including&#xD;
             expected cooperation of the patients for the treatment and follow-up, must be obtained&#xD;
             and documented according to the local regulatory requirements&#xD;
&#xD;
          -  The patient must be accessible for treatment and follow-up&#xD;
&#xD;
        Additional Inclusion criteria for participation in the HER2+/HR+ sub-protocol:&#xD;
&#xD;
          -  Confirmed ER and/or PR positive and HER2+ by central pathology&#xD;
&#xD;
          -  Clinical cT1c - T4a-c (participation of patients with tumors &gt;cT2 is strongly&#xD;
             recommended)&#xD;
&#xD;
          -  All clinical N (participation of patients with cN0, if cT1c is strongly recommended)&#xD;
&#xD;
          -  Patients must qualify for neoadjuvant treatment&#xD;
&#xD;
          -  LVEF &gt; 50%; LVEF within normal limits of each institution measured by echocardiography&#xD;
             and normal ECG (within 42 days prior to induction treatment)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity reaction to the compounds or incorporated substances&#xD;
&#xD;
          -  Prior malignancy with a disease-free survival of &lt; 10 years, except curatively treated&#xD;
             basalioma of the skin, pTis of the cervix uteri&#xD;
&#xD;
          -  Non-operable breast cancer including inflammatory breast cancer&#xD;
&#xD;
          -  Previous or concurrent treatment with cytotoxic agents for any reason after&#xD;
             consultation with the sponsor&#xD;
&#xD;
          -  Concurrent treatment with other experimental drugs. Participation in another clinical&#xD;
             trial with any investigational not marketed drug within 30 days prior to study entry&#xD;
&#xD;
          -  Male breast cancer&#xD;
&#xD;
          -  Concurrent pregnancy; patients of childbearing potential must implement&#xD;
&#xD;
          -  a highly effective (less than 1% failure rate) non-hormonal contraceptive measures&#xD;
             during the study treatment&#xD;
&#xD;
          -  Breast feeding woman&#xD;
&#xD;
          -  Sequential breast cancer&#xD;
&#xD;
          -  Reasons indicating risk of poor compliance Patient not able to consent&#xD;
&#xD;
        Additional Exclusion Criteria for participation in the HER2+/HR+ sub-protocol:&#xD;
&#xD;
          -  Known polyneuropathy ≥ grade 2&#xD;
&#xD;
          -  Severe and relevant co-morbidity that would interact with the application of cytotoxic&#xD;
             agents or the participation in the study&#xD;
&#xD;
          -  Inadequate organ function (e.g. hepatic impairment, pulmonary disease, etc.)&#xD;
&#xD;
          -  Uncompensated cardiac function (current unstable ventricular arrhythmia&#xD;
&#xD;
          -  requiring treatment, history of symptomatic CHF NYHA classes II-IV), history of&#xD;
             myocardial infarction or unstable angina pectoris within 6 months of enrollment,&#xD;
             history of severe hypertension, CAD - coronary artery disease)&#xD;
&#xD;
          -  Severe dyspnea&#xD;
&#xD;
          -  Pneumonitis&#xD;
&#xD;
        Abnormal blood values:&#xD;
&#xD;
          -  Thrombocytopenia &gt; CTCAE grade 1&#xD;
&#xD;
          -  Increases in ALT/AST &gt; CTCAE grade 1&#xD;
&#xD;
          -  Hypokalaemia &gt; CTCAE grade 1&#xD;
&#xD;
          -  Neutropenia &gt; CTCAE grade 1&#xD;
&#xD;
          -  Anaemia &gt; CTCAE grade 1&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadia Harbeck, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Breast Center of the University of Munich (LMU), Universitätsfrauenklinik Großhadern, Munich, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrike Nitz, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Ev. Krankenhaus Bethesda Brustzentrum Niederrhein, Mönchengladbach, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Breast Center of the University of Munich (LMU)</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ev. Krankenhaus Bethesda Brustzentrum Niederrhien</name>
      <address>
        <city>Mönchengladbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Hofmann D, Nitz U, Gluz O, Kates RE, Schinkoethe T, Staib P, Harbeck N. WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial. Trials. 2013 Aug 19;14:261. doi: 10.1186/1745-6215-14-261.</citation>
    <PMID>23958221</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>November 30, 2012</study_first_submitted>
  <study_first_submitted_qc>December 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2012</study_first_posted>
  <last_update_submitted>July 20, 2019</last_update_submitted>
  <last_update_submitted_qc>July 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

